EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tri‐Parametric Assessment of α‐Galactosidase A Activity, lysoGb3 and X‐Inactivation Aids Genotype‐Phenotype Categorization of Fabry Disease Female Patients

Ladislav Kuchar, Lenka Dvorakova, Linda Berna, Martin Reboun, Petra Slavikova, Radovan Bakalar, Jana Ledvinova, Helena Poupetova, Petr Ruzicka, Asfaw Befekadu, Gabriela Dostalova iD, Stella Reichmannova und 2 weitere

Journal of Inherited Metabolic Disease · 2026-07 · 49 (4)

DOI: 10.1002/jimd.70218 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Inherited Metabolic Disease, online erschienen am 22.06.2026. Verfasst von Ladislav Kuchar und 13 weiteren Autor:innen. Beteiligte Einrichtung: Research Unit for Rare Diseases, Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and Gener…. Hauptthemen laut MEDLINE: Fabry Disease, alpha-Galactosidase, X Chromosome Inactivation, Glycolipids. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerstvo Zdravotnictví Ceské Republiky, Ministerstvo Školství, Mládeže a Tělovýchovy, European Union.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fabry disease (FD, OMIM 301500) is an X‐linked lysosomal storage disorder caused by deficient activity of lysosomal alpha‐galactosidase A (AGAL, E.C. 3.2.1.22) due to pathogenic variants in the GLA gene (HGNC:4296, Xq22.1). Plasmatic deacylated globotriaosylceramide (lysoGb3) is elevated in FD patients as a reflection of lysosomal accumulation of Gb3. Specific (AGALopathic) GLA variants have been recently shown to accumulate within the secretory pathway and trigger endoplasmic reticulum stress and unfolded protein response rather than result in profound enzymatic deficiency. In part due to lack of integrative measures of clinical severity and biochemical/molecular parameters, specific impacts and consequences of X‐chromosomal inactivation (XCI) on clinical manifestation in FD female heterozygotes still remain to be fully understood. Our study aimed at evaluation of XCI (% of inactive wt GLA allele) in untreated female FD heterozygotes with classic FD ( n = 17), late‐onset FD ( n = 19) and individuals carrying GLA variants (p.(L394P) ( n = 7), p.(A143T) ( n = 4), and p.(D313Y) ( n = 4)) with predominant AGALopathic effects. XCI was correlated with age of the patients, clinical phenotype, (residual) AGAL activity, and lysoGb3. AGAL activity corresponded to XCI independently of the type of the GLA mutation. The best separation of the clinical phenotypes (classic FD, late‐onset FD and AGALopathy) was achieved by correlating XCI to the ratio of AGAL activity to lysoGb3. This three parametric calculated marker was then confronted with the Mainz Severity Score Index (MSSI) to generate an Integrative Clinical‐Laboratory quotient (ICLq). ICLq discriminated the three female patient groups and demonstrated group‐dependent differences in its average age‐related increase.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fabry Diseasealpha-GalactosidaseX Chromosome InactivationGlycolipidsSphingolipidsHumansFemaleAdultPhenotypeMiddle AgedGenetic Association StudiesAdolescentGenotypeYoung AdultAgedHeterozygoteMutationChild

Stichwörter der Autor:innen

AGALopathyFabry diseaseX‐chromosome inactivationalpha‐galactosidase Agenotype‐phenotype correlationlysoGb3

Substanzen

alpha-GalactosidaseGlycolipidsSphingolipidsglobotriaosyl lysosphingolipidGLA protein, human

Autor:innen und Institutionen

  • Research Unit for Rare Diseases, Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
  • Diagnostic Laboratories of Inherited Metabolic Diseases, Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
  • Second Department of Internal Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
  • Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.

ORCID-Profile: Gabriela Dostalova, Ales Linhart

Förderung

  • Ministerstvo Zdravotnictví Ceské Republiky
  • Ministerstvo Školství, Mládeže a Tělovýchovy
  • European Union
  • Univerzita Karlova v Praze
  • Sanofi
  • Grantová Agentura, Univerzita Karlova
  • European Commission

Zitieren

APA

Kuchar, L., Dvorakova, L., Berna, L., Reboun, M., Slavikova, P., Bakalar, R., Ledvinova, J., Poupetova, H., Ruzicka, P., Befekadu, A., Dostalova, G., Reichmannova, S., Linhart, A., & Sikora, J. (2026). Tri‐Parametric Assessment of α‐Galactosidase A Activity, lysoGb3 and X‐Inactivation Aids Genotype‐Phenotype Categorization of Fabry Disease Female Patients. Journal of Inherited Metabolic Disease, 49(4). https://doi.org/10.1002/jimd.70218

Vancouver

Kuchar L, Dvorakova L, Berna L, Reboun M, Slavikova P, Bakalar R, et al. Tri‐Parametric Assessment of α‐Galactosidase A Activity, lysoGb3 and X‐Inactivation Aids Genotype‐Phenotype Categorization of Fabry Disease Female Patients. Journal of Inherited Metabolic Disease. 2026;49(4). doi:10.1002/jimd.70218

BibTeX
@article{Kuchar2026,
  author = {Kuchar, Ladislav and Dvorakova, Lenka and Berna, Linda and Reboun, Martin and Slavikova, Petra and Bakalar, Radovan and Ledvinova, Jana and Poupetova, Helena and Ruzicka, Petr and Befekadu, Asfaw and Dostalova, Gabriela and Reichmannova, Stella and Linhart, Ales and Sikora, Jakub},
  title = {Tri‐Parametric Assessment of α‐Galactosidase A Activity, lysoGb3 and X‐Inactivation Aids Genotype‐Phenotype Categorization of Fabry Disease Female Patients},
  journal = {Journal of Inherited Metabolic Disease},
  year = {2026},
  volume = {49},
  number = {4},
  doi = {10.1002/jimd.70218}
}
Kostenlos starten →